🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06719466
Active, not recruiting Not applicable

Diet Intervention on Obesity Related Complication

NCT06719466 · tracked via the Priya Life Science China tracker
Sponsor
Zhang Manna
Phase
Not applicable
Started
2024-09-01
Last updated
2024-12-05

Condition(s) studied

ObeseStomach Diseases

Investigational drug(s) / intervention(s)

low linoleic acid (LA)

low linoleic acid (LA): diet guidance with low linoleic acid (LA) diet

Study summary

Obesity has become a global epidemic, with more than 4 billion people expected to be overweight/obese by 2035, accounting for more than half of the world's population. Currently, there are sixteen recognized complications directly related to obesity, including gastroesophageal reflux disease. In recent years, people have increasingly paid attention to the damage caused by obesity to the stomach. In addition to gastroesophageal reflux disease, obesity also leads to various forms of gastric mucosal damage related diseases, such as gastric ulcers, chronic gastritis, intestinal metaplasia, and so on. This stuty aimed to observe the diet intervention on obesity related stomach.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Obtain informed consent before carrying out any trial-related activity, which is any procedure carried out as part of a trial, including the identification of activities suitable for the trial 2. Men and premenopausal women, ages 18-65 at the time of signing the informed consent form 3. Obese patients are diagnosed based on a body mass index (BMI) of 28-40kg/m2 Exclusion Criteria: 1)Patients who do not possess or lose the ability to make their judgment, are unable to understand the purpose of the study, or are unwilling to cooperate with it; 2) Heart, liver, kidney dysfunction,and systemic diseases, such as various malignant tumors, systemic allergic diseases, and autoimmune diseases; 3)Drug or alcohol dependence, intellectual disability, mental disorders; 4)Pregnant and lactating women; 5) Confirmed Helicobacter pylori infection (PPI, bismuth, and antibiotics were stopped for at least 4 weeks, and any of the following tests were positive: non-invasive HP test such as urea breath test, monoclonal stool Helicobacter pylori antigen test, serum soluble Helicobacter pylori antigen test; Invasive Hp test included rapid urease test and tissue section staining); 6)diagnosis of acute gastric mucosal lesions; 7)the patient was diagnosed with chronic gastritis according to the new Sydney system visual simulation scoring method and the pathological diagnostic criteria of chronic gastritis in China; 8) histological and imaging examinations, adenocarcinoma was diagnosed.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Endocrinology, Shanghai Tenth People's Hospital Shanghai China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06719466 on ClinicalTrials.gov ↗ ← All trials in China